TRPV1-Dependent Autonomic Control in Diabetes

TRPV1 依赖性糖尿病自主控制

基本信息

  • 批准号:
    8694847
  • 负责人:
  • 金额:
    $ 33.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-04-01 至 2019-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Systemic glucose homeostasis is substantially regulated by central autonomic circuits and there is a high risk of developing type 2 diabetes if autonomic dysfunction is present. Therefore, without a full understanding of the mechanisms governing the preautonomic neurons, there is a barrier to the understanding of the control of glycemic status. The overall long term goal of this proposal is to elucidate the fundamental relationship between central autonomic control and glucose homeostasis. The paraventricular nucleus (PVN) of the hypothalamus is a critical command center controlling autonomic outflow and, thereby, influencing glucose and energy homeostasis. Since impaired glucose homeostasis in diabetic patients involves central circuits controlling autonomic output, the immediate objective of this proposal is to identify transient receptor potential vanilloid type 1 (TRPV1)-dependent mechanisms involved in the regulation of preautonomic PVN neurons in the control of glycemic status using in vivo and in vitro approaches. The involvement of TRPV1 in diabetes has been established and recent studies from my laboratory have indicated that TRPV1 is a vital controller of preautonomic PVN neurons through increasing excitatory neurotransmitter release. Furthermore, this TRPV1- dependent excitation of liver-related PVN neurons was absent in a diabetic mouse model. Our preliminary observations demonstrate that activation of TRPV1 in the PVN lowers systemic blood glucose levels in control mice likely through increasing glucose uptake of the muscle and decreasing gluconeogenesis by the liver. These observations lead to the central hypothesis that preautonomic PVN neurons receive TRPV1-expressing inputs and these inputs are integrated into a coordinated autonomic output signal to generate an appropriate glycemic response. The proposed in vivo studies will determine the effect of TRPV1 activation in PVN circuits on autonomic endpoints. The effect of TRPV1 activation in PVN on glucose homeostasis will be determined using hyperinsulinemic-euglycemic clamp studies in conscious mice, and on blood pressure and heart rate using telemetry. Systems level studies using optogenetics will determine the effect of selective stimulation and inhibition of TRPV1 inputs on glucose homeostasis using TRPV1cre mice. Whole-cell, patch-clamp studies will reveal the cellular effects of activation and inhibition of TRPV1 inputs on PVN neurons, and we will identify preautonomic neuronal populations in the PVN regulated by TRPV1-expressing projections. Furthermore, the effect of TRPV1 activation on neurotransmission will be determined using photostimulation in TRPV1cre mice. These studies will define the role of central TRPV1 action on whole body glucose homeostasis through preautonomic PVN neurons, and will differentiate the importance of pre- and postsynaptic locations of TRPV1 on this system. The outcomes of the proposed studies hold the promise of opening innovative clinical strategies and drug targets for the improvement of glycemic status in diabetic patients via autonomic control.
描述(由申请人提供):全身葡萄糖稳态基本上由中枢自主神经回路调节,如果存在自主神经功能障碍,则存在患 2 型糖尿病的高风险。因此,如果不充分了解控制前自主神经元的机制,对血糖状态控制的理解就会存在障碍。该提案的总体长期目标是阐明中枢自主控制与葡萄糖稳态之间的基本关系。下丘脑的室旁核(PVN)是控制自主神经流出的关键指挥中心,从而影响葡萄糖和能量稳态。由于糖尿病患者的葡萄糖稳态受损涉及控制自主神经输出的中枢回路,因此该提案的直接目标是使用体内和体外方法确定瞬态受体电位香草酸1型(TRPV1)依赖性机制,该机制涉及调节自主神经前PVN神经元以控制血糖状态。 TRPV1 与糖尿病的关系已经确定,我实验室最近的研究表明,TRPV1 通过增加兴奋性神经递质的释放,是自主神经前 PVN 神经元的重要控制器。此外,这种 TRPV1 依赖性肝脏相关 PVN 神经元的兴奋在糖尿病小鼠模型中不存在。我们的初步观察表明,PVN 中 TRPV1 的激活可能通过增加肌肉的葡萄糖摄取和减少肝脏的糖异生来降低对照小鼠的全身血糖水平。这些观察结果得出了一个中心假设,即前自主性 PVN 神经元接收表达 TRPV1 的输入,并且这些输入被整合到协调的自主输出信号中以产生适当的血糖反应。拟议的体内研究将确定 PVN 回路中 TRPV1 激活对自主神经终点的影响。 PVN 中 TRPV1 激活对葡萄糖稳态的影响将通过在清醒小鼠中进行高胰岛素-正常血糖钳夹研究来确定,并通过遥测技术来确定对血压和心率的影响。使用光遗传学的系统级研究将确定 TRPV1cre 小鼠选择性刺激和抑制 TRPV1 输入对葡萄糖稳态的影响。全细胞膜片钳研究将揭示 TRPV1 输入激活和抑制对 PVN 神经元的细胞影响,并且我们将鉴定 PVN 中受 TRPV1 表达投射调节的前自主神经元群体。此外,TRPV1 激活对神经传递的影响将通过 TRPV1cre 小鼠的光刺激来确定。这些研究将通过自主神经前 PVN 神经元定义中枢 TRPV1 作用对全身葡萄糖稳态的作用,并将区分 TRPV1 在此系统中突触前和突触后位置的重要性。拟议研究的结果有望开辟创新的临床策略和药物靶点,通过自主控制改善糖尿病患者的血糖状态。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrea Zsombok其他文献

Andrea Zsombok的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrea Zsombok', 18)}}的其他基金

Impact of estradiol on the central regulation of glucose homeostasis and subsequent implications for hippocampal function.
雌二醇对葡萄糖稳态中枢调节的影响以及随后对海马功能的影响。
  • 批准号:
    10334235
  • 财政年份:
    2022
  • 资助金额:
    $ 33.49万
  • 项目类别:
Impact of estradiol on the central regulation of glucose homeostasis and subsequent implications for hippocampal function.
雌二醇对葡萄糖稳态中枢调节的影响以及随后对海马功能的影响。
  • 批准号:
    10579251
  • 财政年份:
    2022
  • 资助金额:
    $ 33.49万
  • 项目类别:
TRPV1-Dependent Autonomic Control in Diabetes
TRPV1 依赖性糖尿病自主控制
  • 批准号:
    9238766
  • 财政年份:
    2014
  • 资助金额:
    $ 33.49万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 33.49万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 33.49万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 33.49万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 33.49万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 33.49万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 33.49万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 33.49万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 33.49万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 33.49万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 33.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了